ArticleNPJ breast cancer2025

Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.

Sylvain Ladoire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.